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Abstract 
Background: Effective drug regimens for the treatment of hepatitis B virus (HBV) infections 
are essential to achieve the World Health Organisation commitment to eliminate viral 
hepatitis by 2030. Lamivudine (3TC) is widely used in countries with high levels of chronic 
HBV, however resistance has been shown to occur in up to 50% of individuals receiving 
continuous monotherapy for 4 years. Telbivudine (LdT) is now more commonly used in place 
of lamivudine but is ineffective against 3TC-resistant HBV. Genotyping and identification of 
resistance-associated substitutions (RAS) is not practical in many locations.  
Objectives: A novel assay was designed to enable HBV genotyping and characterisation of 
resistance mutations directly from serum samples stored on filter paper, using Sanger and 
MinION sequencing. 
Study design: The assay was applied to a cohort of 30 samples stored on filter paper for 
several years with HBV viral loads ranging from 8.2x108 to 635 IU/mL. A set of 6 high-titre 
samples were used in a proof-of-principle study using the MinION sequencer. 
 Results: The assay allowed determination of HBV genotype and elucidation of RAS down to 
600 IU/mL using a 550bp amplicon. Sequencing of a 1.2kb amplicon using a MinION 
sequencer gave results consistent with Sanger and allowed the identification of minor 
populations of variants. 
Conclusions: We present two methods for reliable HBV sequencing and RAS identification 
using methods suitable for resource-limited environments. This is the first demonstration of 
extraction-free DNA sequencing direct from DSS using MinION and these workflows are 
adaptable to the investigation of other DNA viruses. 
 
*Abstract
 Genotyping and screening for resistance associated substitutions in hepatitis B virus 
genomes is possible using an extraction-free method with dried serum spots (DSS) 
and direct PCR enzymes. 
 Longer fragments can be recovered from high-titre samples and are suitable for 
deep sequencing using the Oxford Nanopore MinION. 





Background and objectives 1 
Hepatitis B virus (HBV) currently infects an estimated 257 million people worldwide and 2 
there is an urgent need for screening and surveillance tools to assess HBV in low and 3 
middle-income countries [1]. In some African regions it is estimated that 6% of the 4 
population are infected and only one in every ten children is vaccinated [2, 3]. HBV has a 5 
complex and error-prone replication cycle and there are many well-characterised mutations 6 
across the HBV genome, conferring resistance to therapy, an increase in replication 7 
efficiency (polymerase), immune- and diagnostic test-escape (S/pre-core), or increased 8 
pathogenicity (reviewed in [4]).  9 
Treatment of chronic HBV typically utilises long term monotherapy with a polymerase 10 
inhibitor. Resistance mutations to the polymerase inhibitor lamivudine (3TC) are well 11 
documented, occurring in 51 % of patients receiving monotherapy for 4 years [5]. 12 
Telbivudine (LdT), which is becoming increasingly more prescribed, is ineffective against 13 
3TC-resistant HBV. Although lamivudine and telbivudine are non-preferred treatment 14 
options, as defined by the American Society for the Study of Liver Diseases (AASLD) and the 15 
European Association for the Study of the Liver (EASL) [6, 7], they remain widely used in 16 
resource-limited countries with high levels of chronic HBV. Furthermore, while tenofovir 17 
(TDF) is the preferred option, 3TC and LdT have been suggested as cost-effective treatments 18 
during pregnancy to limit vertical transmission [8, 9].  19 
An added complication in HBV therapy is the use of 3TC for the treatment of HIV. 3TC 20 
currently forms part of large -scale anti-HIV programs in parts of Africa, however HBV 21 
prevalence and the impact of HIV treatment on HBV resistance associated substitutions 22 
(RAS) is not effectively monitored [10, 11].  23 
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A primary biomarker informing clinical management of chronic HBV is the serum level of 24 
hepatitis B surface antigen (HBsAg). Several mutations are known to lead to low or false-25 
negative results in diagnostic quantification assays (reviewed in [12]), but these mutations 26 
are not routinely investigated. Greater understanding of diagnostic escape mutations will 27 
inform improved patient management. 28 
RAS-typing and genotyping can be achieved by several methods. Sanger sequencing is the 29 
gold standard in clinical applications and represents the most accessible and affordable 30 
choice globally, with some countries able to access overnight sequencing from room 31 
temperature-shipped PCR products. Additionally, the introduction of third-generation 32 
sequencing platforms such as the Oxford Nanopore Technologies (ONT) MinION enables 33 
sequencing with no theoretical upper limit on read length, enabling sequencing of entire 34 
genes or viral genomes in a single read. The MinION sequencer is extremely portable, being 35 
powered through a laptop, and has been used effectively during the Ebola outbreak in West 36 
Africa [13] and in tracking the spread of Zika virus in Brazil [14]. Field application of the 37 
MinION platform has been enhanced with recent advances including improved R9.4 flow 38 
cells with increased accuracy and software such as Nanopolish [15], which works with 39 
signal-level data from the sequencer allowing generation of more accurate consensus 40 
sequences. More recently, a methodology for the MinION platform has been developed and 41 
applied to HBV sequencing and haplotyping which utilises the circular nature of the genome 42 
to generate concatenated single genome replicates [16]. While this work marked a 43 
significant technical innovation, it has limited application to diverse clinical samples due to 44 
the high viral load required for the sample (>108 IU/ml), as therapy is recommended when 45 
serum HBV DNA is as low as >2,000 IU/ml (and other criteria are met) [6, 7].  46 
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Here we combined both Sanger and MinION sequencing with dried serum spot (DSS) 47 
sampling and extraction-free direct PCR to develop proof-of-principle workflows for 48 
generating clinically relevant HBV sequence data in regions without access to conventional 49 
sample storage or a cold chain. A range of primers were developed and assessed targeting 50 
the overlapping ORFs containing S and the reverse transcriptase (RT) domain of the 51 
polymerase gene, which facilitated genotyping and RAS-typing. As the HBV genome is a DNA 52 
molecule it allows a clinical sample to be added directly to a PCR mix with no prior 53 
extraction. While this work was conducted with dried serum spots, it would be compatible 54 
with dried blood spot samples and a range of pathogens with DNA genomes.  55 
Study design 56 
 57 
Samples: All HBV DNA-positive samples were surplus material obtained for routine 58 
diagnostics. A Brazilian cohort obtained from eight centres in São Paulo State were sampled 59 
between July 2016 and April 2017. Virus titre was determined by RealTime HBV 60 
Amplification kit (Abbott). Iraqi samples were collected and processed at the Erbil Central 61 
Laboratory in 2017 and viral load was determined by Artus HBV PCR kit (Qiagen). Sera were 62 
stored at -20°C before preparation of DSS cards. All samples were obtained for routine 63 
diagnostic investigation of HBV, and collection of surplus material from this consented 64 
activity was locally approved by both institutes (Adolfo Lutz Institute, Brazil; University of 65 
Sulaimani, Iraq) for the extended diagnostic development presented in this study. 66 
Sample preparation: 25-30 µL serum was spotted onto a Whatman® Protein SaverTM 903 67 
Card (GE Healthcare), saturating the 12 mm diameter area demarcated on the DSS cards. 68 
Cards were air-dried at room temperature for ~2 h and stored at 4°C with Silica gel sachets. 69 
Samples were stored under these conditions for up to 2 years before the work presented 70 
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here was carried out. Reactions were prepared using a hole punch with a 3 mm diameter, 71 
each filter paper punch representing ~1.5 µL of serum. To prevent cross-contamination a 72 
punch of clean filter paper was performed between each sample. A clean filter paper 73 
(punched directly after the final sample) was included in each PCR run as a negative control. 74 
To determine the level of carryover using this protocol, reactions were set up using the 75 
most sensitive assay (F1/R1 primers, table 1), and 9 high titre samples (ranging from 109 to 76 
106 IU/mL) were intermingled with samples with low or undetectable viral loads, with no 77 
amplification observed in samples with low or negligible HBV titre . 78 
PCR: Primers are shown in table 1. Phusion Blood Direct (Thermo Fisher) was used in 25 µL 79 
reactions (12.5 µL 2x Phusion Blood Direct mastermix, 0.5 µM of each primer). 3 mm 80 
punches taken from DSS cards were then added directly to each tube. PCRs were performed 81 
as follows: 98 C for 5 minutes, 55 X [98 C for 1 second, 50 C for 5 seconds and 72 C for 82 
20 seconds/kb], final extension 72 C for 1 minute.  83 
Sanger sequencing: PCR products were diluted 1:10 with nuclease-free water for Sanger 84 
sequencing (Source Bioscience, Nottingham, UK) using primers F1+R1 or F2+R2 for short and 85 
long amplicons, respectively. Reads were assembled into contiguous sequences and aligned 86 
using MUSCLE in MEGA X [17, 18].  87 
MinION sequencing library preparation: MinION-barcoded samples were prepared using a 88 
two stage PCR and SQK-LWB001 library preparation kit (ONT). First round PCR was carried 89 
out as above, using 25 µL Hemo KlenTaq reactions with 3 mm punches from DSS and 90 
primers F3 and R3 (table 1). 1 µL of reaction product was used as template for a 50 µl PCR: 91 
25 µL 2x LongAmp HotStart Taq master mix, 1.5 µL of barcoded primer mix (ONT) and 22.5 92 
µL nuclease free water. Purified PCR products were quantified by Qubit using the dsDNA 93 
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high sensitivity kit (Thermo Fisher). Based on the method developed by Quick et al. [14], 94 
amplicons were pooled to achieve a total of 0.3 pM input DNA per MinION flow cell 95 
(~260 ng total DNA for a 1.3 kb amplicon). Following adapter ligation, the library was run for 96 
48 hrs on a R9.4.1 flowcell on a MinION Mk II controlled through MinKNOW 1.10.16 97 
software followed by base-calling using Albacore 2.2.2. Adapter-trimmed sequences were 98 
uploaded to the NCBI Sequence Read Archive under project ID PRJNA521740. 99 
MinION sequencing analysis: Basecalled reads were trimmed using Porechop 0.2.3 using 100 
high stringency settings (--discard_middle and --require_two_barcodes) and retained when 101 
Porechop and Albacore barcode aligners agreed. NanoPlot was used to inspect read quality 102 
and length, and reads were filtered based on length (min.: 1200; max.: 1300) using NanoFilt 103 
[19]. Consensus sequences were assembled de novo from processed reads using Canu 104 
(v1.7.1) [20]. The same reads were subsequently aligned using Minimap2 [21] to their 105 
respective Canu consensus sequences. This alignment was used as the input for further 106 
processing in Nanopolish v0.10.2 [15], using the Variants module and the --fix-107 
homopolymers function to generate a corrected consensus sequence. Corrected nanopore 108 
consensus sequences were aligned using MUSCLE within MEGA X to their respective Sanger 109 
contigs to assess sequence similarity. A full description of the bioinformatics workflow used 110 
is included as supplementary data.  111 
Genotyping and variant calling: Genotypes were determined using the web-based tools 112 
HBV geno2pheno [22] and HBVseq [23] following removal of primer sequences. For samples 113 
sequenced by MinION potential intra-host variants were screened for by aligning processed, 114 
filtered reads to the corresponding Sanger sequence. This alignment was then used as the 115 
input for LoFreq [24]. Considering the relatively high error rate of individual nanopore reads, 116 
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variants below a 10% threshold were filtered out, and variants with significant strand bias 117 
were filtered using the default LoFreq settings. Primer sites were masked from the 118 
alignments used for variant calling. 119 
 120 




Sanger sequencing direct from DSS and genotyping 123 
Initially, primer pair F1/R1 was used with Phusion Blood Direct polymerase for the analysis 124 
of 30 HBV-positive serum samples of defined viral load isolated in Brazil. Amplicons were 125 
achieved for all but 3 samples using these primers, facilitating genotyping (table 2). Of the 126 
27 amplified samples, genotype was distributed as follows: A1 n=7, A2 n=3, B1 n=1, D1 n=1, 127 
D2 n=2, D3 n=8, F1 n=1, F2 n=3. A single sample, Br28, was classed as genotype A but did 128 
not match any subtype sequences in geno2pheno. 129 
RAS characterisation 130 
The amplicon produced from the F2/R2 primers permitted Sanger sequencing across aa 169 131 
to aa 250 of the reverse transcriptase (RT) domain of the Pol gene (figure 1, highlighted in 132 
red), which is the region critical to identification of RAS. Of those samples for which an 133 
amplicon was obtained, 5/25 contained known polymerase RAS (table 2). A further 4 134 
samples contained minor peaks on Sanger traces at known RAS sites (table 2). 135 
MinION sequencing direct from DSS 136 
Having obtained clinically relevant sequence data by Sanger sequencing from DSS, we 137 
investigated whether comparable data could be obtained using MinION sequencing in a 138 
small proof-of-principle study. Three high titre samples were selected from the Brazilian 139 
cohort (Br1, Br2, Br3), along with three samples from a separate cohort sourced from the 140 
Kurdistan region of Iraq. The samples sourced from Iraq all had a viral load >108 IU/mL. All 141 
samples were successfully amplified and Sanger sequenced using F1/R1 and F2/R2 primer 142 
pairs initially. An attempt was made to amplify whole HBV genomes from DSS using our 143 
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direct PCR protocol and a previously published primer set [25], however this was 144 
unsuccessful regardless of viral load. 145 
Amplicons of 1,274 bp were successfully generated using primers F3 and R3. A total of 146 
185,349 raw reads were obtained for the 6 samples, ranging from 23869 to 41392 per 147 
barcode. Following adapter trimming and further filtering of erroneously long and short 148 
reads these counts ranged from 7676 to 11832 per barcode (table 3). A summary of raw 149 
sequencing reads acquired over time, and average quality score per read over time is 150 
included in figure 2.  151 
De novo consensus sequence building 152 
Consensus sequences were assembled using Canu. Following initial assembly, the only 153 
errors observed were single base deletions within homopolymers when compared to Sanger 154 
sequences, ranging from 5 to 12 deletions (data not shown). Following a single round of 155 
Nanopolish processing all consensus sequences were identical to their Sanger counterparts 156 
(figure 3).  157 
Detection of minor variants 158 
Several putative minor variants were detected following alignment of MinION reads with 159 
the de novo consensus sequence. The majority of these were filtered out by LoFreq. A single 160 
variant was detected in sample Iq3, an A > G switch in 19% of reads coding for N155D within 161 
the spacer region of polymerase. Inspection of the Sanger trace confirmed the presence of 162 





Methods to both genotype and characterise therapeutic and diagnostic mutations can be 166 
technically, logistically or financially challenging in regions of the world with a high 167 
prevalence of chronic HBV infection. We developed two workflows for generating 168 
sequencing data from DSS using Sanger and MinION platforms, obtaining fully analysed 169 
sequences in less than 48 hours for both methods from receipt of samples. Deep sequencing 170 
data were successfully generated for all six of the samples tested and, following in silico 171 
processing, produced consensus sequences that were identical to the sequences generated 172 
by Sanger sequencing.  173 
While both sequencing methods involve specific expenses, once established they are cost-174 
effective, require no cold chain, and the PCR achieved a lower limit of detection of 175 
approximately 600 IU/mL for small amplicons. This level of sensitivity makes both workflows 176 
viable options for informing clinical decisions as the recommended limit set for initiating 177 
therapy is 2,000 IU/mL [6, 7]. However, while the direct PCR method used here worked well 178 
for partial gene amplicons at low viral loads, it was not successful when applied to 179 
previously published primer sets for amplifying the entire HBV genome [25] (data not 180 
shown), suggesting traditional extraction methods may be preferable for larger (>1.5kb) 181 
amplicons.  182 
Several  RAS detected in this cohort are clinically significant. The Y100C mutant in the S 183 
region of HBsAg has been linked to false negative/low HBsAg tests interpreted as occult 184 
infection [26]. This variant was unusually common in our Brazilian cohort, being present in 185 
5/10 genotype A samples, compared to only 2.8% of genotype A samples analysed in a 186 
separate study, from South Africa [27].  187 
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Our PCR approach specifically targeted the RT domain of Pol to characterise drug resistance 188 
mutants. This is particularly important for application in countries where drugs with a low 189 
barrier to resistance are commonly prescribed. The V173L, L180M and M204V RAS detected 190 
in the polymerase gene indicated resistance to the nucleoside analogues lamivudine and 191 
entecavir [28]. The N236S mutation has not been previously described, but other mutations 192 
at this site have been shown to lead to breakthrough on adefovir [29] and decrease the 193 
efficacy of tenofovir in vitro [30]. Further research is required to determine if N236S 194 
produces a similar phenotype. Finally M250I, present in one sample as a heterozygous peak 195 
in Sanger sequencing, has been shown to lead to lamivudine and telbivudine resistance [28]. 196 
Complex selection pressures on HBV lead to evolution of intra-host subpopulations [31]. 197 
Accurately determining minor variants and haplotypes is potentially of great clinical value, 198 
particularly for a virus requiring long-term therapy allowing the expansion of multi-drug 199 
resistant haplotypes. By applying a conservative variant calling approach we identified one 200 
minor variant sequence using the MinION workflow (N155D in sample Iq3). This variant was 201 
subsequently confirmed by visual analysis of the Sanger read. As residue 155 is located in 202 
the spacer region of polymerase it is unlikely to be clinically significant but highlights the 203 
potential for detecting low-level variants. Multi-drug resistant populations can arise through 204 
sequential RAS introduction over time [32]. Long read high-throughput sequencing 205 
technologies such as nanopore allow characterisation of the changing population of HBV 206 
variants in high titre samples, which has previously required clonal analysis combined with 207 





We acknowledge a number of limitations of this study. Large amplicons were chosen to 211 
utilise nanopore sequencing directly from DSS in this proof-of-concept study, but greater 212 
sensitivity could be achieved using a PCR-tiling approach of two or more amplicons that are 213 
pooled before sequencing (as demonstrated with the much larger Zika virus genome [14]), 214 
or by scaling up reaction mixtures and using more DSS per reaction. Identical sequences 215 
were also observed in two pairs of high viral load samples chosen for nanopore sequencing. 216 
To confirm that this was not an artefact introduced by cross-contamination during 217 
processing, additional, independent DSS punches were taken and sequenced following 218 
direct PCR amplification from these samples to verify the sequences. Given the low 219 
substitution rate of HBV and the fact that these pairs of patients were sampled from the 220 
same geographic region it is likely that these are genuinely identical sequences. However, 221 
errors in preparing DSS cards cannot be discounted. Although we observed no carryover 222 
between high titre samples and those with an undetectable viral load, more stringent 223 
decontamination between punches could be considered if this workflow was applied in a 224 
clinical setting. We also highlight issues with obtaining amplicons >1.5kb using the direct 225 
PCR enzyme, which limits the ability of this direct method to detect linked mutations in long 226 
genomes.  227 
 228 
In summary, we describe two approaches for rapid genotyping and RAS detection in HBV, 229 
using a novel analyte, dried serum spots, which are applicable in resource-limited settings 230 
and require little existing infrastructure. The results presented here demonstrate the utility 231 
of direct PCR enzymes and DSS together in a clinical context. We have also demonstrated, 232 
for the first time, that nanopore sequencing can be applied directly to samples amplified 233 
12 
 
from DSS, with no requirement for extraction. Reliable sequence data was generated using 234 
the MinION sequencer, significantly reducing the requirements for laboratory 235 
infrastructure.  236 
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Figure captions 335 
 336 
 337 
Figure 1. Cartoon highlighting the locations of PCR amplicons. Overlapping ORFs in the HBV 338 
genome (genotype A reference isolate X02763) are shown in blue. PCR amplicons generated 339 
in this study are shown in orange, and the crucial RT region associated with treatment 340 
resistance mutations (aa169 – 250) is shown in red. The F1+R1 amplicon is sufficient for 341 
genotyping and limited detection of sAg diagnostic escape mutants. The region of the 342 
reverse transcriptase (RT) domain in which resistance associated substitutions (RAS) arise 343 
(aa169 – 250), shown in red, is encompassed by the F2+R2 amplicon.  344 
 345 
Figure 2. Metrics from MinION sequencing run. Both plots were generated from raw reads 346 
assigned barcodes by Albacore without further filtering. Quality scores are standard Phred 347 
scores produced by Albacore during basecalling, data is presented as mean Phred score per 348 
read with min and max. 349 
 350 
 351 
Figure 3: Maximum likelihood tree comparing sequences sourced from direct PCR using 352 
both Sanger and nanopore sequencing methods. Nanopore data was first analysed using 353 
Nanopolish, before comparing to Sanger sequences. Sequences were generated using the 354 
amplicons generated from the F3/R3 primers. The ML tree was inferred using a general time 355 
reversible model within MEGA X [17]. Statistical robustness was assessed using bootstrap 356 







Background and objectives 1 
Hepatitis B virus (HBV) currently infects an estimated 257 million people worldwide and 2 
there is an urgent need for screening and surveillance tools to assess HBV in low and 3 
middle-income countries [1]. In some African regions it is estimated that 6% of the 4 
population are infected and only one in every ten children is vaccinated [2, 3]. HBV has a 5 
complex and error-prone replication cycle and there are many well-characterised mutations 6 
across the HBV genome, conferring resistance to therapy, an increase in replication 7 
efficiency (polymerase), immune- and diagnostic test-escape (S/pre-core), or increased 8 
pathogenicity (reviewed in [4]).  9 
Treatment of chronic HBV typically utilises long term monotherapy with a polymerase 10 
inhibitor. Resistance mutations to the polymerase inhibitor lamivudine (3TC) are well 11 
documented, occurring in 51 % of patients receiving monotherapy for 4 years [5]. 12 
Telbivudine (LdT), which is becoming increasingly more prescribed, is ineffective against 13 
3TC-resistant HBV. Although lamivudine and telbivudine are non-preferred treatment 14 
options, as defined by the American Society for the Study of Liver Diseases (AASLD) and the 15 
European Association for the Study of the Liver (EASL) [6, 7], they remain widely used in 16 
resource-limited countries with high levels of chronic HBV. Furthermore, while tenofovir 17 
(TDF) is the preferred option, 3TC and LdT have been suggested as cost-effective treatments 18 
during pregnancy to limit vertical transmission [8, 9].  19 
An added complication in HBV therapy is the use of 3TC for the treatment of HIV. 3TC 20 
currently forms part of large -scale anti-HIV programs in parts of Africa, however HBV 21 
prevalence and the impact of HIV treatment on HBV resistance associated substitutions 22 
(RAS) is not effectively monitored [10, 11].  23 
*Manuscript (Tracked Changes)
Click here to view linked References
2 
 
A primary biomarker informing clinical management of chronic HBV is the serum level of 24 
hepatitis B surface antigen (HBsAg). Several mutations are known to lead to low or false-25 
negative results in diagnostic quantification assays (reviewed in [12]), but these mutations 26 
are not routinely investigated. Greater understanding of diagnostic escape mutations will 27 
inform improved patient management. 28 
RAS-typing and genotyping can be achieved by several methods. Sanger sequencing is the 29 
gold standard in clinical applications and represents the most accessible and affordable 30 
choice globally, with some countries able to access overnight sequencing from room 31 
temperature-shipped PCR products. Additionally, the introduction of third-generation 32 
sequencing platforms such as the Oxford Nanopore Technologies (ONT) MinION enables 33 
sequencing with no theoretical upper limit on read length, enabling sequencing of entire 34 
genes or viral genomes in a single read. The MinION sequencer is extremely portable, being 35 
powered through a laptop, and has been used effectively during the Ebola outbreak in West 36 
Africa [13] and in tracking the spread of Zika virus in Brazil [14]. Field application of the 37 
MinION platform has been enhanced with recent advances including improved R9.4 flow 38 
cells with increased accuracy and software such as Nanopolish [15], which works with 39 
signal-level data from the sequencer allowing generation of more accurate consensus 40 
sequences. More recently, a methodology for the MinION platform has been developed and 41 
applied to HBV sequencing and haplotyping which utilises the circular nature of the genome 42 
to generate concatenated single genome replicates [16]. While this work marked a 43 
significant technical innovation, it has limited application to diverse clinical samples due to 44 
the high viral load required for the sample (>108 IU/ml), as therapy is recommended when 45 
serum HBV DNA is as low as >2,000 IU/ml (and other criteria are met) [6, 7].  46 
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Here we combined both Sanger and MinION sequencing with dried serum spot (DSS) 47 
sampling and extraction-free direct PCR to develop proof-of-principle workflows for 48 
generating clinically relevant HBV sequence data in regions without access to conventional 49 
sample storage or a cold chain. A range of primers were developed and assessed targeting 50 
the overlapping ORFs containing S and the reverse transcriptase (RT) domain of the 51 
polymerase gene, which facilitated genotyping and RAS-typing. As the HBV genome is a DNA 52 
molecule it allows a clinical sample to be added directly to a PCR mix with no prior 53 
extraction. While this work was conducted with dried serum spots, it would be compatible 54 
with dried blood spot samples and a range of pathogens with DNA genomes.  55 
Study design 56 
 57 
Samples: All HBV DNA-positive samples were surplus material obtained for routine 58 
diagnostics. A Brazilian cohort obtained from eight centres in São Paulo State were sampled 59 
between July 2016 and April 2017. Virus titre was determined by RealTime HBV 60 
Amplification kit (Abbott). Iraqi samples were collected and processed at the Erbil Central 61 
Laboratory in 2017 and viral load was determined by Artus HBV PCR kit (Qiagen). Sera were 62 
stored at -20°C before preparation of DSS cards. All samples were obtained for routine 63 
diagnostic investigation of HBV, and collection of surplus material from this consented 64 
activity was locally approved by both institutes (Adolfo Lutz Institute, Brazil; University of 65 
Sulaimani, Iraq) for the extended diagnostic development presented in this study. 66 
Sample preparation: 25-30 µL serum was spotted onto a Whatman® Protein SaverTM 903 67 
Card (GE Healthcare), saturating the 12 mm diameter area demarcated on the DSS cards. 68 
Cards were air-dried at room temperature for ~2 h and stored at 4°C with Silica gel sachets. 69 
Samples were stored under these conditions for up to 2 years before the work presented 70 
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here was carried out. Reactions were prepared using a hole punch with a 3 mm diameter, 71 
each filter paper punch representing ~1.5 µL of serum. To prevent cross-contamination a 72 
punch of clean filter paper was performed between each sample. A clean filter paper 73 
(punched directly after the final sample) was included in each PCR run as a negative control. 74 
To determine the level of carryover using this protocol, reactions were set up using the 75 
most sensitive assay (F1/R1 primers, table 1), and 9 high titre samples (ranging from 109 to 76 
106 IU/mL) were intermingled with samples with low or undetectable viral loads, with no 77 
amplification observed in samples with low or negligible HBV titre . 78 
PCR: Primers are shown in table 1. Phusion Blood Direct (Thermo Fisher) was used in 25 µL 79 
reactions (12.5 µL 2x Phusion Blood Direct mastermix, 0.5 µM of each primer). 3 mm 80 
punches taken from DSS cards were then added directly to each tube. PCRs were performed 81 
as follows: 98 C for 5 minutes, 55 X [98 C for 1 second, 50 C for 5 seconds and 72 C for 82 
20 seconds/kb], final extension 72 C for 1 minute.  83 
Sanger sequencing: PCR products were diluted 1:10 with nuclease-free water for Sanger 84 
sequencing (Source Bioscience, Nottingham, UK) using primers F1+R1 or F2+R2 for short and 85 
long amplicons, respectively. Reads were assembled into contiguous sequences and aligned 86 
using MUSCLE in MEGA X [17, 18].  87 
MinION sequencing library preparation: MinION-barcoded samples were prepared using a 88 
two stage PCR and SQK-LWB001 library preparation kit (ONT). First round PCR was carried 89 
out as above, using 25 µL Hemo KlenTaq reactions with 3 mm punches from DSS and 90 
primers F3 and R3 (table 1). 1 µL of reaction product was used as template for a 50 µl PCR: 91 
25 µL 2x LongAmp HotStart Taq master mix, 1.5 µL of barcoded primer mix (ONT) and 22.5 92 
µL nuclease free water. Purified PCR products were quantified by Qubit using the dsDNA 93 
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high sensitivity kit (Thermo Fisher). Based on the method developed by Quick et al. [14], 94 
amplicons were pooled to achieve a total of 0.3 pM input DNA per MinION flow cell 95 
(~260 ng total DNA for a 1.3 kb amplicon). Following adapter ligation, the library was run for 96 
48 hrs on a R9.4.1 flowcell on a MinION Mk II controlled through MinKNOW 1.10.16 97 
software followed by base-calling using Albacore 2.2.2. Adapter-trimmed sequences were 98 
uploaded to the NCBI Sequence Read Archive under project ID PRJNA521740. 99 
MinION sequencing analysis: Basecalled reads were trimmed using Porechop 0.2.3 using 100 
high stringency settings (--discard_middle and --require_two_barcodes) and retained when 101 
Porechop and Albacore barcode aligners agreed. NanoPlot was used to inspect read quality 102 
and length, and reads were filtered based on length (min.: 1200; max.: 1300) using NanoFilt 103 
[19]. Consensus sequences were assembled de novo from processed reads using Canu 104 
(v1.7.1) [20]. The same reads were subsequently aligned using Minimap2 [21] to their 105 
respective Canu consensus sequences. This alignment was used as the input for further 106 
processing in Nanopolish v0.10.2 [15], using the Variants module and the --fix-107 
homopolymers function to generate a corrected consensus sequence. Corrected nanopore 108 
consensus sequences were aligned using MUSCLE within MEGA X to their respective Sanger 109 
contigs to assess sequence similarity. A full description of the bioinformatics workflow used 110 
is included as supplementary data.  111 
Genotyping and variant calling: Genotypes were determined using the web-based tools 112 
HBV geno2pheno [22] and HBVseq [23] following removal of primer sequences. For samples 113 
sequenced by MinION potential intra-host variants were screened for by aligning processed, 114 
filtered reads to the corresponding Sanger sequence. This alignment was then used as the 115 
input for LoFreq [24]. Considering the relatively high error rate of individual nanopore reads, 116 
6 
 
variants below a 10% threshold were filtered out, and variants with significant strand bias 117 
were filtered using the default LoFreq settings. Primer sites were masked from the 118 
alignments used for variant calling. 119 
 120 




Sanger sequencing direct from DSS and genotyping 123 
Initially, primer pair F1/R1 was used with Phusion Blood Direct polymerase for the analysis 124 
of 30 HBV-positive serum samples of defined viral load isolated in Brazil. Amplicons were 125 
achieved for all but 3 samples using these primers, facilitating genotyping (table 2). Of the 126 
27 amplified samples, genotype was distributed as follows: A1 n=7, A2 n=3, B1 n=1, D1 n=1, 127 
D2 n=2, D3 n=8, F1 n=1, F2 n=3. A single sample, Br28, was classed as genotype A but did 128 
not match any subtype sequences in geno2pheno. 129 
RAS characterisation 130 
The amplicon produced from the F2/R2 primers permitted Sanger sequencing across aa 169 131 
to aa 250 of the reverse transcriptase (RT) domain of the Pol gene (figure 1, highlighted in 132 
red), which is the region critical to identification of RAS. Of those samples for which an 133 
amplicon was obtained, 5/25 contained known polymerase RAS (table 2). A further 4 134 
samples contained minor peaks on Sanger traces at known RAS sites (table 2). 135 
MinION sequencing direct from DSS 136 
Having obtained clinically relevant sequence data by Sanger sequencing from DSS, we 137 
investigated whether comparable data could be obtained using MinION sequencing in a 138 
small proof-of-principle study. Three high titre samples were selected from the Brazilian 139 
cohort (Br1, Br2, Br3), along with three samples from a separate cohort sourced from the 140 
Kurdistan region of Iraq. The samples sourced from Iraq all had a viral load >108 IU/mL. All 141 
samples were successfully amplified and Sanger sequenced using F1/R1 and F2/R2 primer 142 
pairs initially. An attempt was made to amplify whole HBV genomes from DSS using our 143 
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direct PCR protocol and a previously published primer set [25], however this was 144 
unsuccessful regardless of viral load. 145 
Amplicons of 1,274 bp were successfully generated using primers F3 and R3. A total of 146 
185,349 raw reads were obtained for the 6 samples, ranging from 23869 to 41392 per 147 
barcode. Following adapter trimming and further filtering of erroneously long and short 148 
reads these counts ranged from 7676 to 11832 per barcode (table 3). A summary of raw 149 
sequencing reads acquired over time, and average quality score per read over time is 150 
included in figure 2.  151 
De novo consensus sequence building 152 
Consensus sequences were assembled using Canu. Following initial assembly, the only 153 
errors observed were single base deletions within homopolymers when compared to Sanger 154 
sequences, ranging from 5 to 12 deletions (data not shown). Following a single round of 155 
Nanopolish processing all consensus sequences were identical to their Sanger counterparts 156 
(figure 3).  157 
Detection of minor variants 158 
Several putative minor variants were detected following alignment of MinION reads with 159 
the de novo consensus sequence. The majority of these were filtered out by LoFreq. A single 160 
variant was detected in sample Iq3, an A > G switch in 19% of reads coding for N155D within 161 
the spacer region of polymerase. Inspection of the Sanger trace confirmed the presence of 162 





Methods to both genotype and characterise therapeutic and diagnostic mutations can be 166 
technically, logistically or financially challenging in regions of the world with a high 167 
prevalence of chronic HBV infection. We developed two workflows for generating 168 
sequencing data from DSS using Sanger and MinION platforms, obtaining fully analysed 169 
sequences in less than 48 hours for both methods from receipt of samples. Deep sequencing 170 
data were successfully generated for all six of the samples tested and, following in silico 171 
processing, produced consensus sequences that were identical to the sequences generated 172 
by Sanger sequencing.  173 
While both sequencing methods involve specific expenses, once established they are cost-174 
effective, require no cold chain, and the PCR achieved a lower limit of detection of 175 
approximately 600 IU/mL for small amplicons. This level of sensitivity makes both workflows 176 
viable options for informing clinical decisions as the recommended limit set for initiating 177 
therapy is 2,000 IU/mL [6, 7]. However, while the direct PCR method used here worked well 178 
for partial gene amplicons at low viral loads, it was not successful when applied to 179 
previously published primer sets for amplifying the entire HBV genome [25] (data not 180 
shown), suggesting traditional extraction methods may be preferable for larger (>1.5kb) 181 
amplicons.  182 
Several  RAS detected in this cohort are clinically significant. The Y100C mutant in the S 183 
region of HBsAg has been linked to false negative/low HBsAg tests interpreted as occult 184 
infection [26]. This variant was unusually common in our Brazilian cohort, being present in 185 
5/10 genotype A samples, compared to only 2.8% of genotype A samples analysed in a 186 
separate study, from South Africa [27].  187 
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Our PCR approach specifically targeted the RT domain of Pol to characterise drug resistance 188 
mutants. This is particularly important for application in countries where drugs with a low 189 
barrier to resistance are commonly prescribed. The V173L, L180M and M204V RAS detected 190 
in the polymerase gene indicated resistance to the nucleoside analogues lamivudine and 191 
entecavir [28]. The N236S mutation has not been previously described, but other mutations 192 
at this site have been shown to lead to breakthrough on adefovir [29] and decrease the 193 
efficacy of tenofovir in vitro [30]. Further research is required to determine if N236S 194 
produces a similar phenotype. Finally M250I, present in one sample as a heterozygous peak 195 
in Sanger sequencing, has been shown to lead to lamivudine and telbivudine resistance [28]. 196 
Complex selection pressures on HBV lead to evolution of intra-host subpopulations [31]. 197 
Accurately determining minor variants and haplotypes is potentially of great clinical value, 198 
particularly for a virus requiring long-term therapy allowing the expansion of multi-drug 199 
resistant haplotypes. By applying a conservative variant calling approach we identified one 200 
minor variant sequence using the MinION workflow (N155D in sample Iq3). This variant was 201 
subsequently confirmed by visual analysis of the Sanger read. As residue 155 is located in 202 
the spacer region of polymerase it is unlikely to be clinically significant but highlights the 203 
potential for detecting low-level variants. Multi-drug resistant populations can arise through 204 
sequential RAS introduction over time [32]. Long read high-throughput sequencing 205 
technologies such as nanopore allow characterisation of the changing population of HBV 206 
variants in high titre samples, which has previously required clonal analysis combined with 207 





We acknowledge a number of limitations of this study. Large amplicons were chosen to 211 
utilise nanopore sequencing directly from DSS in this proof-of-concept study, but greater 212 
sensitivity could be achieved using a PCR-tiling approach of two or more amplicons that are 213 
pooled before sequencing (as demonstrated with the much larger Zika virus genome [14]), 214 
or by scaling up reaction mixtures and using more DSS per reaction. Identical sequences 215 
were also observed in two pairs of high viral load samples chosen for nanopore sequencing. 216 
To confirm that this was not an artefact introduced by cross-contamination during 217 
processing, additional, independent DSS punches were taken and sequenced following 218 
direct PCR amplification from these samples to verify the sequences. Given the low 219 
substitution rate of HBV and the fact that these pairs of patients were sampled from the 220 
same geographic region it is likely that these are genuinely identical sequences. However, 221 
errors in preparing DSS cards cannot be discounted. Although we observed no carryover 222 
between high titre samples and those with an undetectable viral load, more stringent 223 
decontamination between punches could be considered if this workflow was applied in a 224 
clinical setting. We also highlight issues with obtaining amplicons >1.5kb using the direct 225 
PCR enzyme, which limits the ability of this direct method to detect linked mutations in long 226 
genomes.  227 
 228 
In summary, we describe two approaches for rapid genotyping and RAS detection in HBV, 229 
using a novel analyte, dried serum spots, which are applicable in resource-limited settings 230 
and require little existing infrastructure. The results presented here demonstrate the utility 231 
of direct PCR enzymes and DSS together in a clinical context. We have also demonstrated, 232 
for the first time, that nanopore sequencing can be applied directly to samples amplified 233 
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from DSS, with no requirement for extraction. Reliable sequence data was generated using 234 
the MinION sequencer, significantly reducing the requirements for laboratory 235 
infrastructure.  236 
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Figure captions 331 
 332 
 333 
Figure 1. Cartoon highlighting the locations of PCR amplicons. Overlapping ORFs in the HBV 334 
genome (genotype A reference isolate X02763) are shown in blue. PCR amplicons generated 335 
in this study are shown in orange, and the crucial RT region associated with treatment 336 
resistance mutations (aa169 – 250) is shown in red. The F1+R1 amplicon is sufficient for 337 
genotyping and limited detection of sAg diagnostic escape mutants. The region of the 338 
reverse transcriptase (RT) domain in which resistance associated substitutions (RAS) arise 339 
(aa169 – 250), shown in red, is encompassed by the F2+R2 amplicon.  340 
 341 
Figure 2. Metrics from MinION sequencing run. Both plots were generated from raw reads 342 
assigned barcodes by Albacore without further filtering. Quality scores are standard Phred 343 
scores produced by Albacore during basecalling, data is presented as mean Phred score per 344 
read with min and max. 345 
 346 
 347 
Figure 3: Maximum likelihood tree comparing sequences sourced from direct PCR using 348 
both Sanger and nanopore sequencing methods. Nanopore data was first analysed using 349 
Nanopolish, before comparing to Sanger sequences. Sequences were generated using the 350 
amplicons generated from the F3/R3 primers. The ML tree was inferred using a general time 351 
reversible model within MEGA X [17]. Statistical robustness was assessed using bootstrap 352 
resampling of 1,000 pseudoreplicates. The tree with the highest log-likelihood is shown. 353 
 354 
Table 1: Primers used for the amplification of HBV. R2 is a modified version of the HBV3 
primer. F3 and R3 primers contain additional 5’ bases for MinION library preparation PCR. 
*Numbering based upon HBVdb genotype A reference strain X02763 [33]. 
 




 F1  GATGTGTCTGCGGCGTTTTA 376 - 395 
Outer minus 
[34]
 R1  CTGAGGCCCACTCCCATAGG 656-637 
- F2  GGAYGGAAAYTGCACYTGTA 583 – 602 
- R2  GRGCAACRGGGTAAAGG 1156 - 1140 
HBVZ 
[35]
 F3  TTTCTGTTGGTGCTGATATTGCAGCCCTCAGGCTCAGGGCATA 3085 – 3105 
HBV3 
[35]




Table 2: Amplification of S/Pol gene from DSS of HBV-positive samples from Brazil, 
allowing genotyping and characterisation of RAS by Sanger sequencing, is dependent on 
viral load. Clinically significant RAS in the reverse transcriptase (RT) domain of the 
Polymerase open reading frame (ORF) are noted. Treatment information: TDF, tenofovir; 
3TC, lamivudine; EFV, efavirenz; U, treatment unknown. Amplification and sequencing 
information: Y, amplification and sequencing successful for given primer set; N, unsuccessful 
amplification for given primer set; NT, sample not tested due to lack of source material; ND, 
no RAS detected in given ORF. Genotype and % confidence data were obtained using HBV 
geno2pheno with F1+R1 sequence data. In the case of sample Br26, the consensus 
sequence was basecalled as R (A/G) at RT site 750, with G leading to the M250I mutant and 
A matching the genotype D reference sequence. The minor peaks column highlights any 




































Br1 816,483,772 No 
treatment 
Y A1 97.6 Y ND Y100C ND 
Br2 389,547,123 Peg-IFN Y A1 97.6 Y ND Y100C ND 
Br3 241,145,063 TDF, 3TC Y D2 98.9 Y V173L, L180M 
M204V 
ND ND 
Br4 33,875,365 TDF, 3TC, 
EFV 
Y A1 97.6 Y ND Y100C ND 
Br5 21,807,740 No 
treatment 
Y D3 98.5 Y ND ND ND 
Br6 6,219,005 TDF Y D3 98.7 Y ND ND ND 
Br7 5,843,310 No 
treatment 
Y A1 97.1 Y ND Y100C ND 
Br8 5,217,998 U Y D2 98.8 Y ND ND ND 




Br10 692,965 U Y A2 99.0 Y ND ND ND 
Br11 193,271 TDF Y F2 97.6 Y ND ND ND 
 
Br12 94,152 U Y D3 97.9 Y N236S ND ND 
 
Br13 59,927 TDF Y D3 98.6 N ND ND ND 
 
Br14 43,005 TDF, 3TC Y A1 97.1 Y ND Y100C ND 
 
Br15 35,672 TDF Y A1 97.6 Y ND ND ND 
 
Br16 25,791 TDF Y D2 95.1 Y S202I ND ND 
 
Br17 17,280 U Y F1 97.3 Y ND ND ND 
 
Br18 16,697 U Y D3 98.7 NT ND ND ND 
 
Br19 12,446 3TC Y D3 98.7 Y ND ND rtI169M, 
rtM204L 
Br20 12,196 No 
treatment 
Y A2 96.2 Y ND ND ND 
 
Br21 10,058 TDF Y F2 97.2 Y ND ND rtI169K, 
rtV173G 
Br22 7,199 TDF N   N    
Br23 6,208 No 
treatment 
Y D3 98.7 Y ND ND ND 
 
Br24 4,091 TDF Y B1 98.5 Y ND ND rtV173G 
Br25 2,884 Peg-IFN Y A1 97.5 N    
Br26 2,431 No 
treatment 




Br27 2,262 No 
treatment 
Y A2 97.7 Y ND ND rtN263K 
Br28 1,069 U N A  Y ND ND ND 
 
Br29 1,046 No 
treatment 
N   N    
Br30 635 No 
treatment 
Y D3 92.6 Y ND ND ND 
 
Table 3. MinION sequencing yields. Raw reads are those assigned barcodes by Albacore 
before any further quality control. Adapter trimmed reads are those exceeding a mean 
Phred score of 7 and processed by Porechop. Length filtered reads were processed by 
NanoFilt. 
 
Sample Viral load (IU/mL) Raw reads Adapter trimming Length filtered 
Br1 816,483,772 24105 13320 11272 
Br2 389,547,123 23868 12640 10309 
Br3 241,145,063 41392 14702 11832 
Iq1 369,094,710 
 
27478 12445 7676 
Iq2 480,199,200 
 
40646 13539 8979 
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Following basecalling using Albacore, the “pass” folder (reads exceeding a mean Phred score 
of 7) was used as the input for Porechop as follows: 
 
porechop -i source_directory --discard_middle --require_two_barcodes 
 
Filtering based on length was carried out for each barcode using NanoFilt: 
 
cat reads.fastq | nanofilt -l 1200 --maxlength 1300 > reads.filtered.fastq 
 
Downsampled, filtered FASTQ files for each sample were then used as the input for Canu: 
 
./canu --nanopore-raw reads.filtered.fastq genomeSize=1300 stopOnReadQuality=false -d 
canu_out -p sample-ID 
 
This generates several candidate contigs, the contig with the highest number of reads used 
was verified using BLAST and taken forwards to the next step. 
 
Reads were then aligned in Minimap2 to their respective contig generated using Canu: 
 
minimap2 -ax map-ont canu_contig.fasta reads.filtered.fastq | samtools view -bS - | 
samtools sort -o sample.minimap.sorted.bam 
 
This alignment was then used to generate a polished consensus sequence using Nanopolish. 
First the reads are indexed to match every read in the .fastq file with its corresponding raw 
fast5 file (the original output of the minION sequencer): 
 
nanopolish index -d fast5_directory -s sequencing_summary.txt reads.filtered.fastq 
 
The alignment, reference contig and fastq for each sample were then used as the input for 
Nanopolish: 
 
nanopolish variants --consensus --fix-homopolymers -b sample.minimap.sorted.bam -g 
canu_contig.fasta -r reads.filtered.fastq -o sample.polished.consensus.vcf 
 
This consensus .vcf file was then converted to standard .fasta format: 
 
nanopolish vcf2fasta -g canu_contig.fasta sample.polished.consensus.vcf > 
sample.polished.consensus.fasta 
 
The output consensus sequence can then be checked against the original Canu contig, as 
well as a Sanger contig from the same sample if available. These sequences can also be used 
for genotyping and resistance typing against established reference sequences. 
 
Supplementary Data
Intra-sample variants can be determined by aligning all reads to the consensus sequence 
and using LoFreq to generate a .vcf file: 
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